Evaluation of optimized bronchoalveolar lavage sampling designs for characterization of pulmonary drug distribution

Abstract

Bronchoalveolar lavage (BAL) is a pulmonary sampling technique for characterization of drug concentrations in epithelial lining fluid and alveolar cells. Two hypothetical drugs with different pulmonary distribution rates (fast and slow) were considered. An optimized BAL sampling design was generated assuming no previous information regarding the pulmonary distribution (rate and extent) and with a maximum of two samples per subject. Simulations were performed to evaluate the impact of the number of samples per subject (1 or 2) and the sample size on the relative bias and relative root mean square error of the parameter estimates (rate and extent of pulmonary distribution). The optimized BAL sampling design depends on a characterized plasma concentration time profile, a population plasma pharmacokinetic model, the limit of quantification (LOQ) of the BAL method and involves only two BAL sample time points, one early and one late. The early sample should be taken as early as possible, where concentrations in the BAL fluid ≥ LOQ. The second sample should be taken at a time point in the declining part of the plasma curve, where the plasma concentration is equivalent to the plasma concentration in the early sample. Using a previously described general pulmonary distribution model linked to a plasma population pharmacokinetic model, simulated data using the final BAL sampling design enabled characterization of both the rate and extent of pulmonary distribution. The optimized BAL sampling design enables characterization of both the rate and extent of the pulmonary distribution for both fast and slowly equilibrating drugs.Electronic supplementary materialThe online version of this article (doi:10.1007/s10928-015-9438-9) contains supplementary material, which is available to authorized users.

Model-Based Drug Development in Pulmonary Delivery: Pharmacokinetic Analysis of Novel Drug Candidates for Treatment of Pseudomonas aeruginosa Lung Infection

“…Although drug transfer between BAL and plasma has been previously described using a modeling approach for the study of other antibiotics and antituberculosis drugs,15, 35, 36, 37 few studies in the literature have simultaneously modeled and analyzed observed drug concentration-time profiles of plasma, BAL, and lung homogenate samples collected from the same animals using a quantitative approach. The results in the present study demonstrate the close relationship between SEN001 concentrations in BAL and the lung.…”

Structure-Based Prediction of Anti-infective Drug Concentrations in the Human Lung Epithelial Lining Fluid

“…An example script is also included as Electronic supplementary material to demonstrate the application of the QSPR model. Conceptually, the model developed in this study could be of considerable relevance to inform and optimize the design of lung PK studies (34). since such studies are methodologically complex and burdensome with respect to the obtaining samples.…”

Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid

“…This may be due to the inherent sparse design consisting of few time points for BAL studies in general, suggesting the need for potential design optimization of such studies. Additional BAL studies may benefit from the use of applying model-based design optimization as described by Clewe et al [44]. Furthermore, various other technical challenges related to ELF collection complicate precise quantification of drug concentration in the ELF [45].…”